Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.41 |
| ▸ | GLP1R | P43220 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9861374 | 0.84 | ALDH1A1 (0.50) | ALDH1A1CYP1A2GAAMAPTNPSR1 | |
| SCHEMBL10317272 | 0.84 | ALDH1A1 (0.50) | ALDH1A1CYP1A2GAAMAPTNPSR1 | |
| SCHEMBL299269 | 0.82 | GAA (0.56) | ALDH1A1CYP1A2GAAMAPTNPC1 | |
| SCHEMBL8726638 | 0.82 | ALDH1A1 (0.51) | ALDH1A1CYP1A2GAAMAPTNPSR1 | |
| SCHEMBL10350633 | 0.82 | ALDH1A1 (0.45) | ALDH1A1CYP1A2GAAMAPTNPSR1 | |
| SCHEMBL595150 | 0.81 | ALDH1A1 (0.69) | ALDH1A1CYP1A2GAAMAPTNPSR1 | |
| SCHEMBL16705221 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP1A2GAAMAPTNPSR1 | |
| SCHEMBL26281760 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP1A2GAAMAPTNPSR1 | |
| SCHEMBL1919483 | 0.81 | ALDH1A1 (0.68) | ALDH1A1CYP1A2GAAMAPTNPSR1 | |
| SCHEMBL16397410 | 0.80 | NPSR1 (0.50) | ALDH1A1MAPTNPSR1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025030117-A1 | FERROPTOSIS INDUCERS | ARPEGGIO BIOSCIENCES, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| WO-2024175925-A1 | MC2R MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2024-08-29 | — | — | WO | disclosed |
| CN-117777051-B | Synthesis method of 2-bromo-5-chlorothiazole-4-carboxylate | 山西永津集团有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117777051-A | Synthesis method of 2-bromo-5-chlorothiazole-4-carboxylate | 山西永津集团有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20220289698-A1 | INHIBITORS OF HUMAN ATGL | Karl-Franzens-Universität Graz (AT) | 2022-09-15 | — | — | US | disclosed |
| WO-2019040511-A1 | DUAL INHIBITORS OF THE BCL-2 AND HDM2 FAMILIES THROUGH CO-MIMICRY OF THE BH3 AND P53-ALPHA-HELICES | UNIVERSITY OF MARYLAND BATIMORE (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040511-A1 | DUAL INHIBITORS OF THE BCL-2 AND HDM2 FAMILIES THROUGH CO-MIMICRY OF THE BH3 AND P53-ALPHA-HELICES | UNIVERSITY OF MARYLAND BATIMORE (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2018177993-A1 | PYRAZOLES FOR CONTROLLING ARTHROPODS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-10-04 | — | — | WO | disclosed |
| EP-3262035-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016135163-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-01 | — | — | WO | disclosed |
| US-20120053149-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-01 | — | — | US | disclosed |
| US-20120053149-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-01 | — | — | US | disclosed |
| US-20120053149-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-01 | — | — | US | disclosed |
| EP-2421859-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-02-29 | — | — | EP | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| WO-2010122504-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010080478-A1 | COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053149-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY1, P2RY2 | ALDH1A1 617/4885CYP1A2 1032/4885GAA 3166/4885 |
| US-20220289698-A1 | INHIBITORS OF HUMAN ATGL | LIPC, LIPG, PNLIP | ALDH1A1 2464/4885CYP1A2 3149/4885GAA 101/4885 |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | ALDH1A1 3814/4885CYP1A2 706/4885GAA 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.